Treatment Choice and Outcomes for End Stage Renal Disease: Evidence from the First Year of a Nationwide Randomized Evaluation

How to cite

Finkelstein, Amy; Ji, Yunan; Mahoney, Neale; Einav, Liran. 2021. "Treatment Choice and Outcomes for End Stage Renal Disease: Evidence from the First Year of a Nationwide Randomized Evaluation." AEA RCT Registry. AEARCTR-0008034. https://doi.org/10.1257/rct.8034-2.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Amy Finkelstein* , Yunan Ji , Neale Mahoney , Liran Einav

* Primary investigator

Registry ID
AEARCTR-0008034
DOI
https://doi.org/10.1257/rct.8034-2.0
First registered
Last updated
Status
Completed
Trial dates
2021-01-01 – 2021-12-31
Countries
United States of America ()
Registry record
http://www.socialscienceregistry.org/trials/8034

Abstract

We plan to analyze the first year of a nationwide randomized-controlled trial of end stage renal disease (ESRD) treatment choice. This mandatory-participation program was designed by the Centers for Medicare and Medicaid Services and randomization was conducted at the hospital referral region (HRR) level. 95 HRRs were assigned to the treatment group beginning in January 2021. We will study the impact of this program in the first year on treatment modality choice for ESRD and explore heterogeneity in impact across patients and providers.

Experimental design

We propose to study the ESRD Treatment Choice (ETC) program, a nationwide randomized-controlled trial (RCT) of ESRD treatment that was designed by the Centers for Medicare and Medicaid Services (CMS) to encourage greater use of home dialysis. The RCT creates payment adjustments for ESRD facilities and clinicians based on the rates of home dialysis and transplantation. The RCT was first announced in July 2019 for a start date of January 1, 2020 which was later delayed to January 1, 2021. In September 2020, 30% of hospital referral regions (HRRs) were assigned to treatment through a stratified randomization procedure. The RCT is scheduled to last until June 2027.
The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.

Design details

Randomization method
HRRs were assigned to treatment through a stratified randomization procedure.
Randomization unit
Hospital Referral Regions (HRRs)
Clusters
302 HRRs
Observations
According to 2016 data, the analysis sample includes approximately 19,000 beneficiaries. We expect a similar number of observations in 2021.
Arms
Treatment: 91 HRRs (estimated 6,000 beneficiaries) Control: 211 HRRs (estimated 13,000 beneficiaries)
Primary outcomes
Percentage of Patients Receiving Any Home Dialysis in the First 90 Days
Secondary outcomes
- Percentage of Weeks Receiving Any Home Dialysis in First 90 Days - Percentage of Dialysis Sessions at Home in First 90 Days - Dialysis Rate per Capita - Total Number of Dialysis Patients - Pre-Dialysis Elixhauser Index - Percentage of Patients Receiving Any Home Dialysis in First 90 Days in 2020

Materials

Papers from this trial

  1. Ji Y, Einav L, Mahoney N, Finkelstein A. Financial Incentives to Facilities and Clinicians Treating Patients With End-stage Kidney Disease and Use of Home Dialysis: A Randomized Clinical Trial. JAMA Health Forum. 2022;3(10):e223503. doi:10.1001/jamahealthforum.2022.3503 https://jamanetwork.com/journals/jama-health-forum/fullarticle/2797080

Cited by

No citation data available for this registration yet.

Keywords